MX2015004703A - Composiciones cancerigenas inyectables. - Google Patents
Composiciones cancerigenas inyectables.Info
- Publication number
- MX2015004703A MX2015004703A MX2015004703A MX2015004703A MX2015004703A MX 2015004703 A MX2015004703 A MX 2015004703A MX 2015004703 A MX2015004703 A MX 2015004703A MX 2015004703 A MX2015004703 A MX 2015004703A MX 2015004703 A MX2015004703 A MX 2015004703A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic
- cancer cells
- cell proliferative
- cancer compositions
- injectable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Se proveen en la presente composiciones de profármacos terapéuticos que pueden ser suministradas a un paciente vía una emulsión inyectable, que comprende un fármaco terapéutico enlazado a un péptido que es eficiente y específicamente escindido por una proteasa seleccionada asociada con un trastorno proliferativo de la célula, incluyendo células cancerígenas, por ejemplo, células cancerígenas de próstata, hígado o pecho, en un paciente. También se proporcionan en la presente métodos para tratar trastornos proliferativos de célula, incluyendo cánceres, con las composiciones de profármacos terapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261714662P | 2012-10-16 | 2012-10-16 | |
PCT/US2013/064889 WO2014062587A2 (en) | 2012-10-16 | 2013-10-14 | Injectable cancer compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015004703A true MX2015004703A (es) | 2015-10-12 |
Family
ID=50488875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015004703A MX2015004703A (es) | 2012-10-16 | 2013-10-14 | Composiciones cancerigenas inyectables. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20150265572A1 (es) |
EP (1) | EP2908838A4 (es) |
JP (1) | JP2015534951A (es) |
KR (1) | KR20150092109A (es) |
CN (1) | CN104870006A (es) |
AU (1) | AU2013331518A1 (es) |
BR (1) | BR112015008421A2 (es) |
CA (1) | CA2888141A1 (es) |
CL (1) | CL2015000923A1 (es) |
EA (1) | EA201590521A1 (es) |
HK (1) | HK1211203A1 (es) |
IL (1) | IL238358A0 (es) |
MX (1) | MX2015004703A (es) |
SG (1) | SG11201502973YA (es) |
WO (1) | WO2014062587A2 (es) |
ZA (1) | ZA201502533B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9737556B2 (en) | 2014-06-13 | 2017-08-22 | Trustees Of Tufts College | FAP-activated therapeutic agents, and uses related thereto |
FR3031678B1 (fr) * | 2015-01-19 | 2019-07-26 | Universite Des Sciences Et Technologies De Lille | Utilisation conjointe de asp-8adt et d'un inhibiteur d'autophagie dans le traitement de cancer. |
CA3203072A1 (en) | 2020-12-22 | 2022-06-30 | Andrea CASAZZA | Compounds comprising a tetrapeptidic moiety |
WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030055052A1 (en) * | 2000-11-10 | 2003-03-20 | Stefan Peters | FAP-activated anti-tumor compounds |
US7468354B2 (en) * | 2000-12-01 | 2008-12-23 | Genspera, Inc. | Tissue specific prodrugs |
US20050049209A1 (en) * | 2003-08-06 | 2005-03-03 | Chen Andrew Xian | Pharmaceutical compositions for delivering macrolides |
US8557861B2 (en) * | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
US20100035824A1 (en) * | 2005-10-12 | 2010-02-11 | Goerne Herbert | Synergistic Pharmaceutical Composition |
US20100047170A1 (en) * | 2006-01-05 | 2010-02-25 | Denmeade Samuel R | Peptide Prodrugs |
US7635682B2 (en) * | 2006-01-06 | 2009-12-22 | Genspera, Inc. | Tumor activated prodrugs |
NZ590730A (en) * | 2008-07-23 | 2012-10-26 | Bharat Serums & Vaccines Ltd | Stable injectable oil-in-water docetaxel nanoemulsion |
WO2010107909A2 (en) * | 2009-03-17 | 2010-09-23 | The Johns Hopkins University | Methods and compositions for the detection of cancer |
CN102939077B (zh) * | 2010-06-03 | 2016-04-06 | 莱迪杜德制药公司 | 含有维生素k的纳米乳液组合物 |
-
2013
- 2013-10-14 US US14/436,479 patent/US20150265572A1/en not_active Abandoned
- 2013-10-14 SG SG11201502973YA patent/SG11201502973YA/en unknown
- 2013-10-14 EP EP13847096.8A patent/EP2908838A4/en not_active Withdrawn
- 2013-10-14 KR KR1020157012889A patent/KR20150092109A/ko not_active Application Discontinuation
- 2013-10-14 CN CN201380063265.XA patent/CN104870006A/zh active Pending
- 2013-10-14 MX MX2015004703A patent/MX2015004703A/es unknown
- 2013-10-14 AU AU2013331518A patent/AU2013331518A1/en not_active Abandoned
- 2013-10-14 JP JP2015536991A patent/JP2015534951A/ja active Pending
- 2013-10-14 CA CA2888141A patent/CA2888141A1/en not_active Abandoned
- 2013-10-14 EA EA201590521A patent/EA201590521A1/ru unknown
- 2013-10-14 WO PCT/US2013/064889 patent/WO2014062587A2/en active Application Filing
- 2013-10-14 BR BR112015008421A patent/BR112015008421A2/pt not_active IP Right Cessation
-
2015
- 2015-04-13 CL CL2015000923A patent/CL2015000923A1/es unknown
- 2015-04-15 ZA ZA2015/02533A patent/ZA201502533B/en unknown
- 2015-04-16 IL IL238358A patent/IL238358A0/en unknown
- 2015-11-23 HK HK15111550.2A patent/HK1211203A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20150265572A1 (en) | 2015-09-24 |
HK1211203A1 (en) | 2016-05-20 |
JP2015534951A (ja) | 2015-12-07 |
EP2908838A2 (en) | 2015-08-26 |
EP2908838A4 (en) | 2016-12-21 |
KR20150092109A (ko) | 2015-08-12 |
BR112015008421A2 (pt) | 2017-08-08 |
CA2888141A1 (en) | 2014-04-24 |
AU2013331518A1 (en) | 2015-04-30 |
WO2014062587A3 (en) | 2014-07-17 |
EA201590521A1 (ru) | 2015-09-30 |
IL238358A0 (en) | 2015-06-30 |
CL2015000923A1 (es) | 2015-08-07 |
ZA201502533B (en) | 2017-11-29 |
CN104870006A (zh) | 2015-08-26 |
SG11201502973YA (en) | 2015-05-28 |
WO2014062587A2 (en) | 2014-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501576A1 (en) | Riluzole prodrugs and their use | |
MX2017007321A (es) | Terapias de combinacion. | |
MX2016001901A (es) | Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno. | |
PH12017550063A1 (en) | Combination therapies for treating cancers | |
JO3556B1 (ar) | علاجات مدمجة لمعالجة السرطان | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
NZ749218A (en) | Androgen receptor modulator and uses thereof | |
IN2014DN11099A (es) | ||
MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
MX359210B (es) | Composición de combinación de pac-1 y tamoxifeno. | |
MX2019001224A (es) | Metodos para tratar el cancer de prostata. | |
PH12015502342A1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
MX2016009284A (es) | Construcciones dirigidas a receptor y sus usos. | |
MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
MX2013002155A (es) | Compuestos para el tratamiento de cancer. | |
MX2018000052A (es) | Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. | |
MX2017006076A (es) | Dianhidrogalactitol junto con radiacion, para tratar carcinoma de pulmón de celulas no pequeñas y glioblastoma multiforme. | |
MX2015011386A (es) | Metodo para tratar cancer pancreatico. | |
MX2015004703A (es) | Composiciones cancerigenas inyectables. | |
MX2014010714A (es) | Terapia de combinacion de procaspasa para gliobastoma. | |
MX2014013763A (es) | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. | |
EA201491352A1 (ru) | Способ лечения рака груди |